New hope for breast cancer patients as life-extending drug now on NHS in England

• Enhertu is now available on the NHS in England, extending median overall survival by approximately seven months in eligible breast cancer patients
• The drug has already demonstrated clinical benefit in Scotland over the past two years, providing real-world evidence of effectiveness
• This expansion represents improved access to a life-extending treatment option for English breast cancer patients previously unable to obtain it through the NHS

Enhertu, which can give patients an extra seven months to live on average, has been prescribed in Scotland for more than two years and is available.

ClinicaliQ summarises and contextualises external updates for clinical awareness, then links to the original publisher for the full article and most current context.